Search hospitals > Indiana > Indianapolis
Franciscan Health Indianapolis
Claim this profileIndianapolis, Indiana 46237
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Adenocarcinoma
178 reported clinical trials
16 medical researchers
Summary
Franciscan Health Indianapolis is a medical facility located in Indianapolis, Indiana. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. Franciscan Health Indianapolis is involved with conducting 178 clinical trials across 269 conditions. There are 16 research doctors associated with this hospital, such as Nibal Saad, Meghana Raghavendra, Taylor M. Ortiz, and Marc Gerdisch, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
ER positive
Stage IV
Top PIs
Nibal SaadMemorial Hospital of South Bend4 years of reported clinical research
Expert in Cancer
Studies Lung Cancer
22 reported clinical trials
56 drugs studied
Meghana RaghavendraFranciscan Health Indianapolis4 years of reported clinical research
Studies Colorectal Cancer
Studies Adenocarcinoma
12 reported clinical trials
28 drugs studied
Taylor M. OrtizFranciscan Health Indianapolis1 year of reported clinical research
Studies Cancer
Studies Breast Cancer
7 reported clinical trials
19 drugs studied
Marc Gerdisch, MDSt Francis Hospital5 years of reported clinical research
Studies Tricuspid Valve Disease
Studies Tricuspid Regurgitation
7 reported clinical trials
8 drugs studied
Clinical Trials running at Franciscan Health Indianapolis
Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Cancer
Colorectal Cancer
Rectal Cancer
Heart Failure
Colon Cancer
Small Cell Lung Cancer
Myocarditis
Sacituzumab Govitecan + Pembrolizumab
for Triple Negative Breast Cancer
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.
Recruiting2 awards Phase 36 criteria
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Franciscan Health Indianapolis?
Franciscan Health Indianapolis is a medical facility located in Indianapolis, Indiana. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. Franciscan Health Indianapolis is involved with conducting 178 clinical trials across 269 conditions. There are 16 research doctors associated with this hospital, such as Nibal Saad, Meghana Raghavendra, Taylor M. Ortiz, and Marc Gerdisch, MD.